Literature DB >> 16997276

Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy.

Sahoko Ichihara1, Yoshiji Yamada, Gaku Ichihara, Hiroaki Kanazawa, Katsunori Hashimoto, Yosuke Kato, Aya Matsushita, Shinji Oikawa, Mitsuhiro Yokota, Mitsunori Iwase.   

Abstract

Oxidative stress is an important susceptibility factor for dilated cardiomyopathy. We have investigated the effects of bisoprolol, a beta1-selective adrenoceptor blocker, on oxidative stress and the development of cardiac dysfunction in a model of dilated cardiomyopathy. Male TO-2 and control hamsters at 8 weeks of age were treated with bisoprolol (5 mg/kg per day) or vehicle for 4 weeks. Treatment with bisoprolol prevented the progression of cardiac dysfunction in TO-2 hamsters. This drug did not affect the increase in NADPH oxidase activity but prevented the reduction in activity and expression of mitochondrial manganese-dependent superoxide dismutase as well as the increases in the concentrations of interleukin-1beta and tumor necrosis factor-alpha in the left ventricle of TO-2 hamsters. Attenuation of the development of cardiac dysfunction by bisoprolol may thus result in part from normalization of the associated increases in the levels of oxidative stress and pro-inflammatory cytokines in the left ventricle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16997276     DOI: 10.1016/j.bbrc.2006.09.026

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The pathological roles of environmental and redox stresses in cardiovascular diseases.

Authors:  Sahoko Ichihara
Journal:  Environ Health Prev Med       Date:  2012-12-29       Impact factor: 3.674

2.  Pretreatment with bisoprolol and vitamin E alone or in combination provides neuroprotection against cerebral ischemia/reperfusion injury in rats.

Authors:  Chiman Salehi; Monireh Seiiedy; Hamid Soraya; Farzaneh Fazli; Morteza Ghasemnejad-Berenji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-27       Impact factor: 3.000

3.  Mitochondrion-toxic drugs given to patients with mitochondrial psychoses.

Authors:  Josef Finsterer
Journal:  Behav Brain Funct       Date:  2012-08-29       Impact factor: 3.759

4.  Effect of exercise training on interleukin-6, tumour necrosis factor alpha and functional capacity in heart failure.

Authors:  Neil A Smart; Alf I Larsen; John P Le Maitre; Almir S Ferraz
Journal:  Cardiol Res Pract       Date:  2011-02-27       Impact factor: 1.866

Review 5.  Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview.

Authors:  Kohzo Nagata; Takuya Hattori
Journal:  Nagoya J Med Sci       Date:  2011-08       Impact factor: 1.131

6.  Involvement of oxidative modification of proteins related to ATP synthesis in the left ventricles of hamsters with cardiomyopathy.

Authors:  Sahoko Ichihara; Yuka Suzuki; Jie Chang; Kentaro Kuzuya; Chisa Inoue; Yuki Kitamura; Shinji Oikawa
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

7.  Left ventricular chamber geometry in cardiomyopathies: insights from a computerized anatomical study.

Authors:  Paulo Sérgio Juliani; João-Carlos Das-Neves-Pereira; Rosangela Monteiro; Aristides Tadeu Correia; Luiz Felipe Pinho Moreira; Fabio Biscegli Jatene
Journal:  ESC Heart Fail       Date:  2018-02-21

Review 8.  Bench-to-bedside review: Beta-adrenergic modulation in sepsis.

Authors:  Etienne de Montmollin; Jerome Aboab; Arnaud Mansart; Djillali Annane
Journal:  Crit Care       Date:  2009-10-23       Impact factor: 9.097

9.  Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results.

Authors:  Marco Metra; Savina Nodari; Tania Bordonali; Patrizia Milani; Carlo Lombardi; Silvia Bugatti; Benedetta Fontanella; Giulia Verzura; Rossella Danesi; Livio Dei Cas
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.